Novartis Sandoz Likely To Set Up Base In Chongqing
This article was originally published in PharmAsia News
Executive Summary
Sandoz China's CEO recently visited Chongqing to check out its business environment. City officials gave details of Chongqing's favorable investment climate, highlighting its pharmaceutical industry infrastructure. Some firms already set up there include Chongqing Yaoyou Pharmaceuticals and Chongqing Southwest Synthetic Pharmaceutical. The city is actively attracting top global 500 companies to build up an industrial manufacturing base, thus the collaboration prospects with Sandoz look promising. Sandoz has expressed optimism in Chongqing's development potential and hopes to work with drug enterprises there to boost the expansion of the local pharmaceutical industry for a win-win relationship. (Click here for more - Chinese Language)
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.